THE 23rd TEL-AVIV UNIVERSITY ALZHEIMER'S DISEASE CONFERENCE
Sponsored by the Sagol School of Neuroscience, the Adams Super Center for Brain Studies, and the Rabin Center for Neurobiology, Tel-Aviv University

June 24-25, 2015

Program

Lectures will be held at the Lola Auditorium, Faculty of Medicine, Tel-Aviv University Campus

WEDNESDAY, JUNE 24, 2015

08:00 – 08:30   Registration

Chair: Amos Korczyn, Danny Michaelson

08:30 - 08:40   Greetings: Geri Roth, Uri Ashery

Session 1  Tau pathology
Session in honor of the late Professor Michele Tansella

Chair: Joab Chapman, Therese Treves

08:40 – 09:20   Johannes Attems (UK)
    Tau-related neurodegeneration

09:20 – 09:40   Hanna Rosenmann
    CSF tau protein in neurodegenerative diseases

09:40 – 10:00   Illana Gozes
    Translational tau: From bench to biotech: ADNP/NAP as a case study

10:00 – 10:20   Ed Stern
    Pathological tau disrupts ongoing network activity

10:20 – 10:40   Hagit Eldar Finkelman
    GSK-3 interacts with lysosome networking and contributes to neurodegeneration

10:40 – 11:10   Coffee break   ☕️
Session 2  Animal models
Chair: Danny Frenkel, Michael Davidson

11:10 – 11:50  Manfred Windisch (Austria)
Focus on tau as therapeutic target: Animal models

11:50 – 12:10  Shira Knafo (Spain)
PTEN controls synaptic and cognitive function in AD models

12:10 – 12:30  Menahem Segal
Stress and AD in triple tg mice

12:30 – 12:50  Daniel Segal
Altered protein glycosylation predicts AD and modulates its pathology

12:50 – 13:10  Eli Ezrielev
Teaching an old mouse new tricks

13:10 – 14:00  Lunch

Session 3  Clinical aspects of AD
Chair: Odelia Elkana, Eli Wertman

14:00– 14:40  Asa Abeliovich (USA)
Epigenetics of AD

14:40 – 15:00  Shahar Arzy
What we talk about when we talk about disorientation in patients with dementia:
Neuropsychological, behavioral and functional imaging evidence

15:00– 15:20  Naomi Nevler
Revision of the CDR scale

15:20 – 15:40  Tamara Shiner
Probing the link between GBA mutations and synucleinopathies
15:40 – 16:00 Coffee break

Session 3 Continued
16:00 – 16:20 Yvonne Freund-Levi (Sweden)
Relation between APOE4 alleles and potential omega-3 fatty acid treatment effects on neuropsychiatric and cognitive symptoms in AD - the OmegAD Study a RCT.

16:20 – 16:40 Ralph Laufer
Teva strategy in neuroscience

Session 4 Swift 5 minutes Student Presentations
Chair: Einor Ben Assayag, Danny Offen

16:40 – 17:15 Shoshik Amram
Transforming Growth Factor β1 signaling in astrocytes mediates astrocytes activity in AD
Anat Boehm-Cagan
ABCA1 agonist peptides: a new therapeutic avenue for the treatment of AD
Korin Ben
Effects of central cholinergic deficits on immunity
Ishai Luz
An anti-apoE4 specific monoclonal antibody counteracts the pathological effects of apoE4 in vivo
Meytal Raizes
Higher normal blood glucose level are associated with decreased processing speed in high functioning young elderly
Ronit Shapira
Hyperbaric oxygen therapy ameliorates the pathophysiology of AD mouse model
Shira Simonovitch
Impaired autophagy in ApoE4 astrocytes
**THURSDAY, JUNE 25, 2015**

**Session 5  Neuroinflammation**
**Session in honor of Mrs Joni Berry Eichenbaum**
**Chair: Ramit Ravona, Orly Weinreb**

08:30 – 09:10  **Howard Weiner** (USA)
Immune mechanisms in AD

09:10 – 09:30  **Alon Monsonego**
Therapeutic translation of brain immune interactions

09:30 – 09:50  **Reuven Stein**
Targeting CD38 attenuates AD pathology in AD-prone mice

09:50 – 10:10  **Danny Frenkel**
**Impairment in astrocyte activity accelerates disease progression in AD mouse model**

10:10 – 10:30  **Assaf Ezra**
Multifunctional effect of human serum albumin towards neuroprotection in AD

10:30 – 11:00  **Coffee break**

**Session 6  New approaches to mitigate AD pathology**
**Chair: Silvia Mandel, Beka Salomon**

11:00 – 11:40  **Gil Rabinovici** (USA)
Imaging tau in humans

11:40 – 12:00  **Gad Marshall** (USA)
Imaging biomarker correlates of neuropsychiatric symptoms in early AD

12:00 – 12:20  **Galit Wainstein**
Serum BDNF and risk of dementia

12:20 – 12:40  **Israel Aharony**
A novel Caspase-6 inhibitor as a potential therapy for AD

12:40 – 13:00  **Uri Ashery**
New approaches to mitigate AD pathology

13:00 – 14:00  Lunch

Session 7  Treatment
Chair: Ruth Gabizon, Zeev Meiner

14:00 – 14:40  Mark Pepys (UK)
Therapeutic targeting of serum amyloid P component in AD

14:40 – 15:00  Abraham Fisher
A novel ultra-potent GPCR-Sigma1 receptor agonist targets major hallmarks of AD

15:00 – 15:20  Liu Wei
Novel multifunctional ChE-MAO inhibitors for treatment of AD

15:20 - 15:30  Danny Michaelson
Development of APOE4 targeted treatment

15:30 – 15:50  Eyal Bar Or
Experience with using TMS combined with cognitive training in Neuronix Israeli AD clinic

15:50 – 16:10  Coffee break

16:10 – 16:30  Gerardo Lederkremer
Genesis of ER stress in Huntington’s and other neurodegenerative diseases

16:30 – 16:50  Amos Korczyn
Risk factors for AD: Implications for therapy

16:50 - 17:30  Round table on treatment and Award for best swift student presentations

Supported by: Avraham Pharma, Enzymotec, NBT, Neuronix, Novartis, Teva